Researchers at City of Hope have identified a new molecular target for treating pancreatic cancer, reports a Gastroenterologystudy published on April 8.
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.
FDA approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.
A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation—KRAS circulating tumor DNA—strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma.
Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.
The Stephenson Global Pancreatic Cancer Research Institute, established to advance early detection, innovative treatments, and groundbreaking research for pancreatic cancer, has launched a call for nominations and Letters of Intent for two award opportunities.
The Stephenson Global Pancreatic Cancer Research Institute is creating new awards to advance pancreatic cancer research.
Researchers at University of California San Diego School of Medicine have discovered that an enzyme called MICAL2 promotes tumor growth and spread in pancreatic ductal adenocarcinomas, the most common form of pancreatic cancer.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults
